Enanta Pharmaceuticals (ENTA) FCF Margin (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly FCF Margin came in at 41.7% in Q1 2026, up 10799.0% YoY from N/an in Q1 2025, and up 33.64% on a QoQ basis from 62.85% in Q4 2025.
Enanta Pharmaceuticals (ENTA) FCF Margin (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 15 years of FCF Margin data on file, last reported at 41.7% in Q1 2026.
- Quarterly FCF Margin rose 10799.0% year-over-year to 41.7% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4.98% (up 11287.0% YoY) and the FY2025 annual result came in at 29.5%, up 9523.0% from the prior year.
- FCF Margin climbed to 41.7% in Q1 2026, from 62.85% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 94.74% in Q2 2025 to a low of 202.24% in Q2 2023.
- A 5-year average of 96.09% and a median of 113.38% in 2024 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin sank 11822 bps — and 2025, when it surged 15754 bps.
- Tracing ENTA's FCF Margin over 5 years: stood at 151.14% in 2022, then climbed by 6 bps to 141.46% in 2023, then climbed by 20 bps to 113.38% in 2024, then jumped by 45 bps to 62.85% in 2025, then surged by 34 bps to 41.7% in 2026.
- The last three FCF Margin figures came in at 41.7% (Q1 2026), 62.85% (Q4 2025), and 32.72% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - | -69.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -69.50% |
| Mar 31, 2026 | -41.70% |
| Dec 31, 2025 | -62.85% |
| Sep 30, 2025 | 32.72% |
| Jun 30, 2025 | 94.74% |
| Mar 31, 2025 | -149.70% |
| Dec 31, 2024 | -113.38% |
| Sep 30, 2024 | -114.29% |
| Jun 30, 2024 | -62.80% |
| Mar 31, 2024 | -181.27% |
| Dec 31, 2023 | -141.46% |
| Sep 30, 2023 | -74.05% |
| Jun 30, 2023 | -202.24% |
| Mar 31, 2023 | -86.48% |
| Dec 31, 2022 | -151.14% |
| Sep 30, 2022 | -84.89% |
| Jun 30, 2022 | -153.19% |
| Mar 31, 2022 | -141.61% |
| Dec 31, 2021 | -48.17% |
| Sep 30, 2021 | -89.17% |